Aspirin in a novel mouse model of metabolic steatotic liver disease and its potential to prevent hepatocellular carcinoma

Abstract

Aspirin shows promise as an accessible approach for preventing liver disease and hepatocellular carcinoma (HCC). Using mouse models combining gene editing and a NASH-inducing diet, aspirin reduced liver inflammation, fibrosis, oxidative stress, and hypoxia, while shifting immune cell profiles toward tissue repair. Key targets included COX-1 and hypoxia pathways. These findings highlight aspirin’s potential as a protective agent in chronic liver disease management and warrant further investigation into its mechanisms and role in HCC prevention.